Top-News

Delmar Pharma News

Keine aktuellen Kursdaten verfügbar
WKN: A2AKGZ
ISIN: US2470782077
Typ: Aktie

Delmar Pharma News

11.07.16 - PR Newswire
DelMar Pharmaceuticals Announces Approval for Listing on NASDAQ
DelMar Pharmaceuticals Announces Approval for Listing on NASDAQ DMPI to Begin Trading on NASDAQ Capital Market on July 12, 2016 PR Newswire
06.06.16 - PR Newswire
DelMar Pharmaceuticals Presents Phase I/II GBM Clinical Trial Data and Outlines Future Clinical Development Plans at ASCO 2016 Annual Meeting
DelMar Pharmaceuticals Presents Phase I/II GBM Clinical Trial Data and Outlines Future Clinical Development Plans at ASCO 2016 Annual Meeting PR Newswire
25.05.16 - PR Newswire
DelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme
DelMar Pharmaceuticals Announces Successful Completion of End-​of-Phase 2 Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme PR Newswire
13.05.16 - PR Newswire
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update - Business update conference call and webcast on May 19, 2016 at 5 ...
05.05.16 - PR Newswire
DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Of Preferred Shares
DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Of Preferred Shares New funds and restructuring of warrants to eliminate a significant portion of derivative ...
21.04.16 - PR Newswire
FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer
FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer New Orphan Designation is the Third Awarded to DelMar Pharmaceuticals by FDA Office of Orphan Products ...
19.04.16 - PR Newswire
DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial with VAL-083 at American Association Cancer Research (AACR) Annual Meeting
DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial with VAL-083 at American Association Cancer Research (AACR) Annual Meeting Results to date ...
19.04.16 - PR Newswire
DelMar Pharmaceuticals Announces New Data Supporting the Unique Anti-cancer Mechanism of VAL-083
DelMar Pharmaceuticals Announces New Data Supporting the Unique Anti-​cancer Mechanism of VAL-083 Unique mechanism of action takes advantage of tumor mutations; ...
18.04.16 - PR Newswire
DelMar's VAL-083 Demonstrates Promise in the Treatment of Non-Small Cell Lung Cancer and Ovarian Cancer
DelMar's VAL-083 Demonstrates Promise in the Treatment of Non-Small Cell Lung Cancer and Ovarian Cancer MD Anderson Researchers Presented New Pre-​clinical Data Today ...
24.03.16 - PR Newswire
DelMar Pharmaceuticals Announces Abstract Presentations for the American Association Cancer Research (AACR) Annual Meeting in April 2016
DelMar Pharmaceuticals Announces Abstract Presentations for the American Association Cancer Research (AACR) Annual Meeting in April 2016 Update on DelMar's Phase I/II ...
15.03.16 - PR Newswire
FDA Grants Second Orphan Designation For VAL-083
FDA Grants Second Orphan Designation For VAL-083 FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for VAL-083 in the treatment of ...
16.02.16 - PR Newswire
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2016 Financial Results and Corporate Update
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2016 Financial Results and Corporate Update - Business update conference call and webcast on February 17, ...
13.01.16 - PR Newswire
DelMar Pharmaceuticals to Collaborate with MD Anderson Cancer Center on Development of DelMar's VAL-083 in Brain Cancer
DelMar Pharmaceuticals to Collaborate with MD Anderson Cancer Center on Development of DelMar's VAL-083 in Brain Cancer - MD Anderson to initiate new clinical studies for the ...
05.01.16 - PR Newswire
DelMar Pharmaceuticals to Present at the Biotech Showcase™ 2016 on January 12, 2016
DelMar Pharmaceuticals to Present at the Biotech Showcase™ 2016 on January 12, 2016 - Presentation with live webcast on Tuesday, January 12th at 11:00 a.m. PT - PR Newswire
23.11.15 - PR Newswire
DelMar Pharmaceuticals Updates VAL-083 Clinical Trial in Refractory Glioblastoma Multiforme at Society for Neuro-Oncology Annual Meeting
DelMar Pharmaceuticals Updates VAL-083 Clinical Trial in Refractory Glioblastoma Multiforme at Society for Neuro-​Oncology Annual Meeting - Interim Phase II data supports ...
19.11.15 - PR Newswire
DelMar Pharmaceuticals to Present at the 8th Annual LD Micro Main Event on December 2, 2015
DelMar Pharmaceuticals to Present at the 8th Annual LD Micro Main Event on December 2, 2015 - Presentation with live webcast on Wednesday, December 2nd at 3:30 p.m. PT - PR ...
17.11.15 - PR Newswire
DelMar Pharmaceuticals Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
DelMar Pharmaceuticals Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update - Management to host business update conference call and ...
13.11.15 - PR Newswire
DelMar Pharmaceuticals Presents Data Summarizing the Potential of VAL-083 as a New Treatment Option for Resistant Cancers
DelMar Pharmaceuticals Presents Data Summarizing the Potential of VAL-083 as a New Treatment Option for Resistant Cancers - VAL-083 offers a promising solution for major ...
11.11.15 - PR Newswire
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors - Preclinical and clinical data support advancement of ...
10.11.15 - PR Newswire
DelMar Pharmaceuticals Collaborators Present Data on the Unique Molecular Mechanisms Responsible for VAL-083 Activity Against Cancer
DelMar Pharmaceuticals Collaborators Present Data on the Unique Molecular Mechanisms Responsible for VAL-083 Activity Against Cancer - Third-​party data further validate ...

Newssuche

Videos

newspaper
24.04.24
Technical Trading: AUD/USD mit Mega Chance
AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »